SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 771.56 |
| Enterprise Value ($M) | 708.76 |
| Book Value ($M) | 701.10 |
| Book Value / Share | 7.68 |
| Price / Book | 1.10 |
| NCAV ($M) | -28.50 |
| NCAV / Share | -0.31 |
| Price / NCAV | -27.07 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.15 |
| Return on Assets (ROA) | -0.11 |
| Return on Equity (ROE) | -0.17 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.65 |
| Current Ratio | 1.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 298.00 |
| Assets | 1,027.60 |
| Liabilities | 326.50 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 837.60 |
| Operating Income | -87.50 |
| Net Income | -127.30 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Increase Decrease Reduction Performance Obligation | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -8.70 |
| Cash from Investing | -11.90 |
| Cash from Financing | -7.40 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Camber Capital Management LP | 3.41 | ||
| 13G/A | Wellington Management Group Llp | 6.60 | -16.83 | |
| 13G/A | Glenview Capital Management, Llc | 1.39 | -76.13 | |
| 13G | Integrated Core Strategies (us) Llc | 5.00 | 1.13 | |
| 13G | Millennium Management Llc | 4.70 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 91,324 | 688,986 | 13.25 | |
| 87,471 | 1,197,364 | 7.31 | |
| 114,913 | 872,971 | 13.16 | |
| 167,525 | 1,215,707 | 13.78 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MRNA – Moderna, Inc. | MRSN – Mersana Therapeutics, Inc. |
| MRVI – Maravai LifeSciences Holdings, Inc. | NBIX – Neurocrine Biosciences, Inc. |
| NEOG – Neogen Corporation |
Financial data and stock pages provided by
Fintel.io